Form 4: Surrozen CFO and COO Charles O. Williams Reports Stock and Option Awards

Charles O. Williams, CFO and COO of Surrozen, Inc., reports the acquisition of restricted stock units and options in the company.

Summary

• Charles O. Williams, the CFO and COO of Surrozen, Inc., filed a Form 4 with the SEC.
• The report details the grant of restricted stock units (RSUs) and options to Williams on May 1, 2025.
• He received 11,250 restricted stock units, each representing a contingent right to receive one share of Surrozen's common stock.
• These RSUs vest over a two-year period, with 50% vesting on each of the first and second annual anniversaries of the grant date, contingent upon continued service.
• Williams also received options to purchase 33,750 shares of common stock at an exercise price of $10.48.
• These options vest over a four-year period in 48 equal monthly installments from the grant date, also contingent upon continued service.
• Following these transactions, Williams directly owns 11,250 RSUs and 33,750 options.
• The options expire on June 1, 2035.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of equity to executives is a standard practice and signals confidence in the company's future. However, it also represents potential dilution for existing shareholders.

Positives

• The grant of RSUs and options to the CFO and COO aligns his interests with those of the shareholders.
• The vesting schedules incentivize continued service and commitment to the company's long-term success.

Industry Context

Stock options and restricted stock units are common forms of compensation for executives in publicly traded companies, particularly in the biotechnology sector, to align their interests with those of shareholders and incentivize long-term growth.

Comparison to Industry Standards

• Equity grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead, and Biogen routinely grant stock options and RSUs to their executives.
• The vesting schedules described are typical, with vesting periods ranging from two to four years to encourage long-term commitment.

Stakeholder Impact

• Shareholders may experience slight dilution due to the issuance of new shares upon vesting of RSUs and exercise of options.
• Employees, particularly the CFO and COO, are incentivized to improve company performance due to their equity stake.

Key Dates

Keywords

Form 4, Surrozen, SRZN, CFO, COO, Charles O. Williams, Restricted Stock Units, Options, Beneficial Ownership, SEC